Efficacy of Fixed-dose Combination of Valsartan + Rosuvastatin Versus Their Isolated Components for Hypertension and Dyslipidemia.
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 02 Feb 2017
At a glance
- Drugs Rosuvastatin/valsartan (Primary) ; Rosuvastatin; Valsartan
- Indications Dyslipidaemias; Hypertension
- Focus Therapeutic Use
- Sponsors EMS
- 25 Jan 2017 Timeframe for primary endpoint has been changed from 4 weeks to 8 weeks. Also treatments arms has been changed from 2 to 4
- 25 Jan 2017 Planned number of patients changed from 334 to 632.
- 25 Jan 2017 Planned End Date changed from 1 May 2017 to 1 May 2018.